Stockreport

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting [Yahoo! Fi...

ArriVent BioPharma, Inc.  (AVBP) 
PDF ArriVent BioPharma, Inc. Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in ce [Read more]